Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (2872)	2/10/2001 12:32:30 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

according to thestreet.bomb (see the two year chart for your latest chuckle)........ quote.yahoo.com >> While the run-up over the past few years has been extensive, other analysts note that there will always be investors who want exposure to red-hot sectors no matter what the cost. << Biotechs went into a horrid drought, 1993-1994. It drove most investors out of the sector. 1995 was characterized by a solid rally, but 1996-1998 was again characterized by a protracted slump for small and mid caps. In 1998, hedge funds were attempting to short small caps into oblivion. 1999 and the first 3 months of 2000 were rally city. Since then, ^BTK is off 27% and small and mid caps have been clobbered. That's a little more than two good years in the last eight. Small caps with innovative projects in the clinic and preclinical development often sell for little more than cash in the bank. The sector is -- and has been -- developing exciting medicines. A dash of liquidity hit in '99 and winter '00. Biotech turns the millennium to be THE sector for huge returns in the next two decades. Thestreet.bomb can't get anything correct, much less their own business plan. It's sort of like the guy/gal who, because AMGN, BGEN, GENZ and were up today, assumes that "biotech" did well. Cramer et al......... go find your clue, and report back!